Clinical Effect of Jianpi Huoxue Prescription Combined with Acupuncture on Chronic Atrophic Gastritis with Gastric Blood Stasis and Its Impact on Inflammatory Indicators and Gastric Mucosal Function
|更新时间:2024-02-28
|
Clinical Effect of Jianpi Huoxue Prescription Combined with Acupuncture on Chronic Atrophic Gastritis with Gastric Blood Stasis and Its Impact on Inflammatory Indicators and Gastric Mucosal Function
Chinese Journal of Experimental Traditional Medical FormulaeVol. 30, Issue 5, Pages: 103-110(2024)
KANG Wenting,SHI Zhaohong,LIU Song,et al.Clinical Effect of Jianpi Huoxue Prescription Combined with Acupuncture on Chronic Atrophic Gastritis with Gastric Blood Stasis and Its Impact on Inflammatory Indicators and Gastric Mucosal Function[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(05):103-110.
KANG Wenting,SHI Zhaohong,LIU Song,et al.Clinical Effect of Jianpi Huoxue Prescription Combined with Acupuncture on Chronic Atrophic Gastritis with Gastric Blood Stasis and Its Impact on Inflammatory Indicators and Gastric Mucosal Function[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(05):103-110. DOI: 10.13422/j.cnki.syfjx.20241092.
Clinical Effect of Jianpi Huoxue Prescription Combined with Acupuncture on Chronic Atrophic Gastritis with Gastric Blood Stasis and Its Impact on Inflammatory Indicators and Gastric Mucosal Function
To explore the application effect of Jianpi Huoxue prescription combined with acupuncture in patients with chronic atrophic gastritis (CAG) of gastric blood stasis type.
Method
2
A total of 86 patients with CAG admitted to Wuhan First Hospital from November 2021 to March 2023 were selected and randomly divided into two groups. The control group was treated with conventional Western medicine, while the observation group was treated with Jianpi Huoxue prescription combined with acupuncture. The clinical efficacy, traditional Chinese medicine (TCM) syndrome score, pathological score, negative conversion rate of Helicobacter pylori (Hp), inflammatory indicators [neutrophils/lymphocytes (NLR) and interleukin (IL)-1
β
], changes in levels of gastric protease (PG) Ⅰ, PG Ⅰ/PG Ⅱ, and gastrin-17 (G-17), and drug safety during treatment were observed after treatment in both groups.
Result
2
After treatment, the total effective rate of the observation group [95.35% (41/43)] was significantly better than that of the control group [79.07% (34/43)], and the difference was statistically significant (
χ
2
=5.108,
P
<
0.05). After treatment, the scores of the primary and secondary TCM syndromes in the observation group and the control group were significantly decreased (
P
<
0.05). After treatment, the scores of primary and secondary TCM syndromes in the observation group were significantly lower than those in the control group (
P
<
0.05). After treatment, the pathological scores of gastric mucosa atrophy, activity, chronic inflammation, intestinal metaplasia, and dysplasia were significantly lower in the observation group and control group (
P
<
0.05). After treatment, the pathological scores of gastric mucosa atrophy, activity, chronic inflammation, intestinal metaplasia, and dysplasia in the observation group were significantly lower than those in the control group (
P
<
0.05). After treatment, the Hp conversion rate in the observation group was significantly increased compared with the control group (
P
<
0.05). After treatment, the levels of inflammatory indicators NLR and IL-1
β
in the observation group and control group were significantly lower (
P
<
0.05), and the levels of inflammatory indicators NLR and IL-1
β
in the observation group were significantly lower than those in the control group (
P
<
0.05). After treatment, the levels of PGI and PGⅠ/PGⅡ in the observation group and control group were significantly higher (
P
<
0.05), and the levels of PGI and PGⅠ/PGⅡ in the observation group were significantly higher than those in the control group (
P
<
0.05). After treatment, the G-17 level of the observation group and the control group was different at different time points (
P
<
0.05), and the G-17 level of the observation group was higher at different time points than that of the control group (
P
<
0.05). The G-17 level of the observation group had an increasing trend compared with the control group (
P
<
0.05). There was no significant difference in the risk of adverse reactions between the two groups.
Conclusion
2
The combination of Jianpi Huoxue prescription and acupuncture can effectively alleviate symptoms, increase Hp negative conversion rate, inhibit inflammation, and regulate PG and G-17 levels in CAG patients, thus controlling or even reversing gastric mucosal atrophy and reducing the probability of its progression to gastric cancer.
关键词
Keywords
references
YIN Y , LIANG H , WEI N , et al . Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020:An updated systematic review and Meta-analysis [J]. Ann Palliat Med , 2022 , 11 ( 12 ): 3697 - 3703 .
SHAH S C , PIAZUELO M B , KUIPERS E J , et al . AGA clinical practice update on the diagnosis and management of atrophic gastritis:Expert review [J]. Gastroenterology , 2021 , 161 ( 4 ): 1325 - 1332 .
CAI Q , SHI P , YUAN Y , et al . Inflammation-associated senescence promotes helicobacter pylori-induced atrophic gastritis [J]. Cell Mol Gastroenterol Hepatol , 2021 , 11 ( 3 ): 857 - 880 .
LAHNER E , CONTI L , ANNIBALE B , et al . Current perspectives in atrophic gastritis [J]. Curr Gastroenterol Rep , 2020 , 22 ( 8 ): 38 .
WANG Y K , SHEN L , YUN T , et al . Histopathological classification and follow-up analysis of chronic atrophic gastritis [J]. World J Clin Cases , 2021 , 9 ( 16 ): 3838 - 3847 .
BOTEZATU A , BODRUG N . Chronic atrophic gastritis:An update on diagnosis [J]. Med Pharm Rep , 2021 , 94 ( 1 ): 7 - 14 .
FANG C , CAO Y , PAN J , et al . Exploration on the acupoint selection rule in modern literature for chronic gastritis treated with acupuncture and moxibustion in recent 10 years [J]. WJAM , 2022 , 32 ( 2 ): 157 - 167 .